Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized open-label study of FS-1502 versus T-DM1 in HER2-positive unresectable locally advanced or metastatic breast cancer
CTR20230426Phase 3Active
- Sponsor
- Fosun Pharma
- Start
- Mar 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of caxmotabart entudotin, trastuzumab emtansine in breast cancer, sponsored by Fosun Pharma. Started Mar 2023; status: active.
02
Drugs
caxmotabart entudotintrastuzumab emtansine
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20230426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230426.